Notice

The database server is currently not answering requests properly. Some pages are still available due to caching. We are investigating the situation and will keep you updated.

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.

Institutions Share
Yale Department of Obstetrics, Gynecology and Reproductive Sciences, United States of America (USA) 0.40
School of Medicine and Surgery, UNIBS, Italy 0.16
Yale Department of Pathology, United States of America (USA) 0.07
Yale Department of Pharmacology, United States of America (USA) 0.07
Laboratory of Human Genetics and Genomics, The Rockefeller University, United States of America (USA) 0.06
Division of Pathological Anatomy, UNIBS, Italy 0.04
Human Oncology and Pathogenesis Program (HOPP), MSKCC, United States of America (USA) 0.02
Department of Human Genetics, UChicago, United States of America (USA) 0.02
Institute of Obstetric and Gynecological Clinic, UCSC, Italy 0.02
IRCCS National Cancer Institute (INT) Milan, Italy 0.02
Yale Department of Genetics, United States of America (USA) 0.02
Department of Cellular and Molecular Medicine (CMM), UC San Diego, United States of America (USA) 0.02
Yale Cancer Center, United States of America (USA) 0.02
Departmental Faculty of Medicine and Surgery, Campus Bio-Medico University, Italy 0.02
Department of Experimental and Clinical Medicine, UMG, Italy 0.01
Fondazione Policlinico Universitario Agostino Gemelli, Italy 0.01
Department of Biomedical Sciences, Korea University, South Korea 0.01

Return